New drug combo targets Hard-to-Treat kidney cancer
NCT ID NCT04895748
First seen Mar 20, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This early-stage study tested a new drug called DFF332 in people with advanced clear cell kidney cancer. The drug works by blocking a protein (HIF2α) that helps some cancers grow. Researchers gave DFF332 alone or with other drugs to see if it was safe and could shrink tumors. The study was stopped early, but the results help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Medical
Duarte, California, 91010, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloane Ketterin Cancer Ctr
New York, New York, 10065, United States
-
Novartis Investigative Site
Brno, 656 53, Czechia
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Koto Ku, Tokyo, 1358550, Japan
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
WA Uni School Of Med
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.